BackDaihan Pharmaceutical Overview

Daihan Pharmaceutical Receivables

Latest receivables for 023910.KS: $32B.

Get informed when a big investor buys or sells

+ Follow
Receivables
$32.25B
↑ 7.22% YoYΔ $2.17B vs prior year quarter

Peer trimmed avg / median

Loading

Daihan Pharmaceutical Receivables History

Loading

Daihan Pharmaceutical vs. peers: Receivables Comparison

Loading

Daihan Pharmaceutical Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Daihan Pharmaceutical (023910.KS) FAQ

As of the most recent data (June 2026), 023910.KS shows a receivables of $32B. That compares with $30B in the prior-year period — up 7.2% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, 023910.KS's receivables is now $32B (was $30B) — a 7.2% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Daihan Pharmaceutical is outperforming or lagging.

Tracking 023910.KS's receivables over time shows whether Daihan Pharmaceutical is scaling, shrinking, or reshaping that part of the business. The current reading is $32B That compares with $30B in the prior-year period — up 7.2% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Daihan Pharmaceutical's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $32B) with ownership activity and broader fundamentals.